New drug cocktail aims to shrink breast tumors before surgery

NCT ID NCT03573648

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) can shrink early-stage, hormone-positive breast tumors before surgery. About 33 women with stage II-III breast cancer will receive the treatment for about 4 months, then have surgery. The goal is to see if this approach leads to a complete response on MRI and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Allegheny Health Network

Pittsburgh, Pennsylvania, 15224, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.